NEW YORK (GenomeWeb News) — Grifols said today that it has been selected by the Japanese Red Cross Society as a partner in nucleic acid screening of the country's 5.3 million annual blood donations.

In a note to investors, Grifols said that the seven-year agreement is worth approximately $375 million. Grifols will provide the JRC with its Procleix Panther system and associated assays, which the JRC will use to screen blood donations for HIV and hepatitis viruses prior to their release for medical use.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.